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Nitric oxide (NO) influences renal blood flow mainly as a result of neuronal nitric oxide synthase (nNOS). Nevertheless, it is
unclear how nNOS expression is modulated by endogenous angiotensin II, an inhibitor of NO function. We tested the hypothesis
that the angiotensin II AT1 receptor and oxidative stress mediated by NADPH oxidase contribute to the modulation of renal nNOS
expression in two-kidney, one-clip (2K1C) hypertensive rats. Experiments were performed on male Wistar rats (150 to 170 g
body weight) divided into 2K1C (N = 19) and sham-operated (N = 19) groups. nNOS expression in kidneys of 2K1C hypertensive
rats (N = 9) was compared by Western blotting to that of 2K1C rats treated with low doses of the AT1 antagonist losartan (10
mg·kg-1·day-1; N = 5) or the superoxide scavenger tempol (0.2 mmol·kg-1·day-1; N = 5), which still remain hypertensive. After 28
days, nNOS expression was significantly increased by 1.7-fold in the clipped kidneys of 2K1C rats and by 3-fold in the non-
clipped kidneys of 2K1C rats compared with sham rats, but was normalized by losartan. With tempol treatment, nNOS
expression increased 2-fold in the clipped kidneys and 1.4-fold in the non-clipped kidneys compared with sham rats. The
changes in nNOS expression were not followed by changes in the enzyme activity, as measured indirectly by the cGMP method.
In conclusion, AT1 receptors and oxidative stress seem to be primary stimuli for increased nNOS expression, but this up-
regulation does not result in higher enzyme activity.
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Introduction
The renin-angiotensin system plays a pivotal role in the
development and maintenance of two-kidney, one clip
(2K1C) Goldblatt hypertension (1,2). The deleterious va-
soconstrictor actions of high tissue levels of angiotensin II
(Ang II) can be partially attenuated by some vasodilator
mechanisms such as nitric oxide (NO) (3). NO is one of the
best vasorelaxant autocoids which, in addition to exerting
systemic control of blood pressure (4), also exerts a para-
crine control of the microvascular tone in the kidney (5).
For example, both acute and chronic inhibition of NO
results in a significant increase in renal vascular resis-
tance, confirming its role in the modulation of renal blood
flow (6-8).
NO is produced by three NO synthase isoforms: the so-
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called inducible (iNOS), endothelial (eNOS) and neuronal
(nNOS) isoforms. Among them, nNOS seems to play an
important protective role in the renal vasculature (9). Selec-
tive chronic inhibition of this isoform leads to arterial hyper-
tension and to a transient sensitization of tubuloglomerular
feedback, indicating a modulatory role of NO derived from
macula densa cells on arteriolar tone and tubuloglomerular
feedback (10). nNOS also seems to be important in counter-
acting Ang II-induced decreases in glomerular filtration rate
via the modulation of tubuloglomerular feedback–mediated
afferent arteriolar constriction and an important influence on
efferent arteriolar tone (11,12).
Although some studies have demonstrated that renal
nNOS expression is altered in experimental models of
hypertension (13-16) and in rats chronically infused with
Ang II (3,17,18), the mechanism by which this endogenous
vasoactive peptide modulates nNOS expression is un-
clear. In the present study, we tested the hypothesis that
Ang II AT1 receptor and/or oxidative stress contribute to the
modulation of renal nNOS expression in rats with Ang II-
dependent hypertension.
Material and Methods
Animals
Male Wistar rats weighing 150 to 170 g were obtained
from the breeding facility of the Federal University of
Espírito Santo, Brazil. The animals received a normal
chow diet and water ad libitum and were housed individu-
ally in temperature-controlled rooms (22°C) under a 12-h
light/dark cycle. All experimental procedures were per-
formed in accordance with the National Institutes of Health
(NIH) Guide for the Care and Use of Laboratory Animals,
and the protocols were previously approved by the Institu-
tional Ethics Committee for Use of Animals (Escola Supe-
rior de Ciências da Santa Casa de Misericórdia de Vitória
– CEUA/EMESCAM).
Renovascular hypertension
2K1C renovascular hypertension was induced by ap-
plying a silver clip with an internal diameter of 0.2 mm to the
left renal artery under chloral hydrate anesthesia (100 mg/
kg, ip). The 2K1C animals (N = 19) were randomly subdi-
vided into 3 groups: a) untreated animals (2K1C, N = 9), b)
animals treated with a subpressor dose of losartan (10
mg·kg-1·day-1, in drinking water), an Ang II subtype AT1
receptor antagonist (2K1C-losartan, N = 5), and c) animals
treated with a subpressor dose of tempol (0.2 mmol·kg-1·
day-1, in drinking water), a mimetic of superoxide dismu-
tase (2K1C-tempol, N = 5). Control sham-operated rats (N
= 5) underwent the same surgical procedure but without
clipping the renal artery. Both the 2K1C and sham groups
were studied 28 days later.
Blood pressure measurements
Four weeks after renal artery clipping or sham opera-
tion, rats were anesthetized with a combination of keta-
mine and xylazine (91.0/9.1 mg/kg, ip) and a catheter was
inserted aseptically into the femoral artery for the direct
measurement of mean arterial pressure (MAP) and heart
rate (HR). The animals then received a single injection of
the antibiotic enrofloxacin (12 mg/kg, im). One day after
catheter placement, MAP and HR were measured in con-
scious, freely moving rats, in their own cages using a
disposable blood pressure transducer (Cobe Laborato-
ries, USA) connected to a pressure processor amplifier
and data-acquisition system (MP100, Biopac Systems,
USA). Data were analyzed on a beat-to-beat basis to
quantify baseline values of MAP and HR.
Western blot analysis
Immediately after euthanasia, blood was removed by
PBS perfusion. The kidney cortex and medulla were sepa-
rated and homogenized with a protease inhibitor cocktail
(Product #P2714, Sigma Aldrich, USA) dissolved in dis-
tilled water at 0.1 μL/mg protein, and centrifuged at 10,000
g for 15 min. Protein concentration was quantified by the
method of Bradford (19). The protein samples (100 μg)
were submitted to SDS-PAGE (5%), under non-reducing
conditions, electroblotting and the test of equal loading of
protein using red Ponceau (GE Healthcare, Germany). If
the homogeneity of protein loading was not confirmed, the
experiment was discarded. When confirmed, nitrocellu-
lose membranes (GE Healthcare) were blocked with 10%
skimmed milk in 0.1% PBS–Tween 20 for 60 min at room
temperature. The membranes were then incubated with a
polyclonal antibody for the nNOS (type I) isoform (Santa
Cruz Biotechnology, USA) at 1:250 dilution at 4°C, fol-
lowed by incubation with horseradish peroxidase-labeled
secondary anti-rabbit antibody (GE Healthcare) at 1:3000
dilution. Bands were detected by enhanced chemilumi-
nescence (GE Healthcare), and band intensity was meas-
ured by densitometry using a Scion Image System (public
domain, NIH, USA). Each electrophoretic run was per-
formed with duplicate samples of both clipped and non-
clipped kidneys from 2K1C and sham animals in the same
polyacrylamide gel. This procedure was repeated for the
2K1C animals treated with losartan or tempol. Rat pituitary
lysate was used as nNOS-positive control.
Quantitation of cyclic GMP levels
The kidneys of several animals were quickly immersed
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in 10 mM PBS containing 3 isobutyl-1-methylxanthine (0.1
mM diluted in DMSO at 1:1000), a nonspecific phosphodi-
esterase inhibitor. The kidneys were then homogenized,
centrifuged (10,000 g for 15 min), immediately frozen in
liquid nitrogen, and stored at -20°C. nNOS bioavailability
was indirectly quantified by an enzyme immunoassay of
cyclic GMP (cGMP) using a specific kit (Product #RPN-
226, GE Healthcare). This was performed in the presence
of acetylated samples to increase the sensitivity of the
assay, as previously reported (20). Data are reported as
fmol/mg protein, with protein being measured by the meth-
od of Bradford (19).
Statistical analysis
Data are reported as means ± SEM. Statistical analysis
was performed by two-way ANOVA followed by the Fisher
post hoc test for multiple comparisons. The level of signif-
icance was set at P < 0.05.
Results
Figure 1 summarizes the resting MAP values obtained
in conscious animals 28 days after renal artery clipping. As
expected, MAP was significantly higher in 2K1C rats (179
± 5 mmHg) than in sham rats (101 ± 3 mmHg, P < 0.01).
Administration of a subpressor dose of losartan, an AT1
receptor antagonist (10 mg·kg-1·day-1), for 4 weeks de-
creased but did not normalize MAP (140 ± 7 mmHg)
compared with sham and 2K1C rats. MAP (165 ± 6 mmHg)
was not decreased in 2K1C animals treated with a low
dose of tempol, a superoxide dismutase mimetic (0.2
mmol·kg-1·day-1), for 4 weeks.
Table 1 shows the kidney weight/body weight ratio of
2K1C rats compared with sham rats. As expected, 4 weeks
after renal artery clipping, hypertensive animals showed a
significant decrease in the weight of the clipped kidney
(atrophy) and a significant increase in the weight of the
non-clipped kidney (hypertrophy) compared with sham
rats. The administration of losartan or tempol for 4 weeks
to 2K1C rats did not prevent the atrophy of the clipped
kidney, but exacerbated the hypertrophy of the non-clipped
kidney.
Figures 2, 3, and 4 show representative Western blot
bands and average values for nNOS protein expression in
the renal cortex of untreated and treated 2K1C rats com-
pared with sham rats. As shown in Figure 2, the 2K1C
hypertensive rats showed increased nNOS protein ex-
pression in the cortex of both clipped and, more exten-
sively, non-clipped kidneys (absorbance: 0.27 ± 0.03 and
0.43 ± 0.03, respectively) compared with the sham group
(absorbance: 0.16 ± 0.03 and 0.14 ± 0.02, respectively; P
Figure 1. Average resting mean arterial pressure in 2-kidney, 1-
clip (2K1C) rats and 2K1C rats treated with low doses of losartan
(10 mg·kg-1·day-1) or tempol (0.2 mmol·kg-1·day-1), compared
with sham rats. Data are reported as means ± SEM for the
number of rats in parentheses. *P < 0.01 vs sham group and +P <
0.05 vs 2K1C group (ANOVA).
Table 1. Kidney weight/body weight ratio in 2-kidney, 1-clip
(2K1C) rats untreated or treated with low doses of losartan (10
mg·kg-1·day-1) or tempol (0.2 mmol·kg-1·day-1) compared with
sham-operated rats.
Group Kidney weight (mg)/body weight (g) ratio
Left kidney Right kidney
(clipped) (non-clipped)
Sham (N = 6) 2.89 ± 0.13 2.94 ± 0.14
2K1C (N = 9) 2.57 ± 0.14# 3.85 ± 0.10*#
2K1C + losartan (N = 5) 2.34 ± 0.07# 4.93 ± 0.18*#+
2K1C + tempol (N = 7) 2.95 ± 0.03 4.85 ± 0.34*#+
Data are reported as means ± SEM. *P < 0.05 vs clipped kidney;
#P < 0.05 vs sham group; +P < 0.05 vs 2K1C (ANOVA).
< 0.05). The treatment of 2K1C rats with a subpressor dose
of losartan prevented the increase of nNOS expression in
the cortex of both clipped and non-clipped kidneys (ab-
sorbance: 0.25 ± 0.03 and 0.22 ± 0.01, respectively)
compared with sham rats (absorbance: 0.29 ± 0.02 and
0.27 ± 0.01, respectively; Figure 3). On the other hand,
treatment of 2K1C rats with a subpressor dose of tempol, a
superoxide dismutase mimetic, prevented the increase of
nNOS expression in the cortex of the clipped, but not of the
non-clipped kidneys (absorbance: 0.35 ± 0.08 and 0.27 ±
0.06, respectively) compared with sham rats (absorbance:
0.17 ± 0.03 and 0.19 ± 0.06, respectively; P < 0.05; Figure 4).
Figure 5 shows the average values of cGMP in the
kidney cortex of the hypertensive 2K1C and sham groups.
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Figure 2. Neuronal nitric oxide synthase (nNOS) protein expres-
sion in clipped (c) and non-clipped (nc) kidney cortex of two-
kidney, 1-clip (2K1C) hypertensive rats compared with sham
rats. The upper panel shows a representative Western blot of
nNOS expression. Data are reported as means ± SEM of nNOS
expression for 9 rats in each group indicated by absorbance
measurements of the Western blot. *P < 0.05 vs sham group; +P
< 0.05 vs non-clipped kidney cortex of 2K1C rats (ANOVA).
Figure 3. Neuronal nitric oxide synthase (nNOS) protein expres-
sion in clipped (c) and non-clipped (nc) kidney cortex of two-
kidney, 1-clip (2K1C) hypertensive rats treated with low doses of
losartan (10 mg·kg-1·day-1) compared with sham rats. The upper
panel shows a representative Western blot of nNOS expression.
Data are reported as means ± SEM of nNOS expression for 4
rats in each group indicated by absorbance measurements of
the Western blot.
Figure 4. Neuronal nitric oxide synthase (nNOS) protein expres-
sion in clipped (c) and non-clipped (nc) kidney cortex of two-
kidney, 1-clip (2K1C) hypertensive rats treated with low doses of
tempol (0.2 mmol·kg-1·day-1) compared with sham rats. The
upper panel shows a representative Western blot of nNOS ex-
pression. Data are reported as means ± SEM of nNOS expres-
sion for 5 rats in each group indicated by absorbance measure-
ments of the Western blot. *P < 0.05 vs sham group (ANOVA).
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The cortex of the clipped kidney showed significantly re-
duced levels of cGMP in untreated 2K1C (0.9 ± 0.06 fmol/
mg protein) and in 2K1C animals treated with a low dose of
losartan (2.5 ± 1.25 fmol/mg protein) or tempol (undetect-
able values) compared with the sham group (31.2 ± 12.2
fmol/mg protein; P < 0.05). In the non-clipped kidney
cortex, the production of cGMP was similar in 2K1C and
sham rats (39.2 ± 14.1 and 53.2 ± 19.3 fmol/mg protein),
but was significantly decreased in 2K1C rats treated with a
subpressor dose of losartan (10.7 ± 5.7 fmol/mg protein) or
tempol (undetectable) compared with sham rats (P < 0.05).
Discussion
The main objective of this study was to evaluate renal
nNOS expression in Goldblatt renovascular hypertension.
The novel finding in this study was that the arterial hyper-
tension following long-term unilateral stenosis of the renal
artery is characterized by an increased expression of
nNOS in the clipped and, more extensively, in the non-
clipped kidney. Our data indicate that AT1 receptors and
oxidative stress could be primary stimuli for the increased
nNOS expression, although the enzyme activity seems to
be diminished, as indirectly indicated by cGMP quantita-
tion.
Losartan at doses of approximately 10 mg/kg has been
used in other experimental models of arterial hypertension
to block AT1 receptors without marked changes in high
blood pressure (21,22). In the present study, we used a
model of Ang II-dependent hypertension and this could
explain why losartan at the dose used attenuated the
increase in MAP. However, losartan-treated 2K1C animals
still showed a marked arterial hypertension compared to
the sham group (140 ± 7 and 101 ± 3 mmHg). On the other
hand, treatment of 2K1C rats with tempol, a specific and
potent short-acting superoxide radical scavenger anion,
did not cause significant changes in MAP.
The contribution of Ang II to the hypertrophy of the non-
clipped kidney of 2K1C animals is not known. In the pres-
ent study, we observed that the 2K1C and mainly the
2K1C-losartan and 2K1C-tempol groups showed an in-
crease in the weight of the non-clipped kidney. The greater
hypertrophy could be due, at least in part, to the blockade
of AT1 receptors in the 2K1C-losartan group and to the
antioxidative stress in both the 2K1C-losartan and 2K1C-
tempol groups.
Our data showing increased nNOS expression in 2K1C
hypertensive rats, an experimental model of increased
intrarenal levels of Ang II (2), support the view that this
enzyme is modulated by the vasoactive peptide Ang II,
exerting a compensatory mechanism in both clipped and
non-clipped kidneys of 2K1C rats. In order to better eluci-
date the mechanisms involved in enhanced nNOS expres-
sion, we also performed the losartan treatment in 2K1C
rats. The restoration of basal levels of nNOS expression by
a low dose of losartan confirmed the hypothesis that nNOS
overexpression is mediated by Ang II through AT1 recep-
tors (23) but not by high blood pressure per se or by other
angiotensin receptors (24). Our result of nNOS overex-
pression in the kidney agrees with the finding that Ang II
blockade leads to an impairment of NO bioavailability (25).
However, the participation of eNOS in 2K1C hypertension
cannot be excluded, in view of the evidence of an increase
of both nNOS and eNOS expression in this model even
under conditions of augmented oxidative stress (26). On
the other hand, the contribution of the iNOS isoform to our
finding can be ruled out based on evidence from the same
investigators showing the absence of an inflammatory
process in both kidneys of chronic 2K1C rats. Interestingly,
nNOS overexpression in 2K1C animals was lower in the
clipped kidney compared with the non-clipped kidney (P <
0.05). Considering the finding that rats subjected to a
Figure 5. cGMP levels in clipped (c) and non-clipped (nc) kidney
cortex of two-kidney, 1-clip (2K1C), 2K1C treated with low doses
of losartan or tempol compared with sham rats. N = 3 in each
group. Data are reported as means ± SEM. *P < 0.05 vs sham
group and +P < 0.05 vs 2K1C group (ANOVA).
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hypobaric environment showed reduced NOS (27), it may
be possible that the hypoxia of the clipped kidneys could
contribute to the attenuated up-regulation of nNOS, even
though this experimental model is characterized by high
levels of intrarenal Ang II (2).
Since NADPH oxidase activity can be stimulated by
AT1 receptors (28), we also investigated the participation
of oxidative stress in nNOS overexpression, and observed
that treatment with tempol restored nNOS expression to
basal levels in the non-clipped kidney. This finding indi-
cated that, in addition to the role played by intracellular
calcium (29), superoxide anions could also participate in
the intracellular mechanism of nNOS up-regulation. Inter-
estingly, nNOS expression in the clipped kidney was in-
creased after the antioxidant treatment. A reasonable ex-
planation for this result is based on previous studies (30,31)
showing high levels of the anti-proteolytic agent hypoxia
inducible factor (HIF-1) under hypoxic conditions. Since
oxidative stress has deleterious effects on HIF-1 expres-
sion (32), it is possible that, under clip-induced renal artery
reduction of blood flow, the antioxidant tempol acted by
preserving HIF-1 expression, consequently inhibiting tis-
sue proteolysis and protecting against nNOS degradation.
The anti-proteolytic effect of HIF-1 could also explain the
smaller atrophy of the clipped kidney of tempol-treated
2K1C rats compared to the other 2K1C groups.
Cervenka et al. (18) reported that the selective antago-
nism of nNOS led to a significant reduction of renal hemo-
dynamics in normotensive rats, but not in Ang II-infused
rats, suggesting that nNOS activity is diminished in hyper-
tensive animals. However, in the present study, we meas-
ured renal nNOS expression and observed that it was
significantly increased in 2K1C hypertensive rats. To rec-
oncile this obvious contradiction, we can assume that the
enzyme activity, but not the protein level of nNOS, is
decreased, as indirectly quantified by the cGMP method.
These data could help explain why the hypertensive Ang
II-infused rats did not present improvement of renal func-
tion in the study by these investigators (18). In agreement
with our results, Murakami et al. (13) showed that nNOS
expression was increased in rats infused with Ang II for 14
days and reduced in DOCA-salt hypertensive rats, a model
of low Ang II levels.
In agreement with our results, there are indications that
systemic oxidative stress is increased in renovascular
hypertension (33,34), which could lead to an enhanced
release of superoxide anions (O2-), mainly due to Ang II
(28,35). Moreover, others have shown that nNOS can
generate superoxide anions, mainly under situations of
depletion of substrates or co-factors (35), also contributing
to O2- production and impaired NO bioavailability. The
reason 2K1C animals treated with low doses of losartan or
tempol showed a marked reduction of cGMP levels may
have been that they were still Ang II-dependent hyperten-
sive when compared with sham animals. In addition, the
low or undetectable levels of cGMP mainly in the non-
clipped kidney of 2K1C-losartan and 2K1C-tempol rats was
expected because the levels of the second messenger
follow the expression of nNOS, which was restored in these
two groups when compared with the 2K1C group. Although
in the present study we did not measure the expression of
eNOS, its participation should be considered.
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